From Nasdaq: 2025-02-13 08:00:00

Eli Lilly and Company (NYSE: LLY) is a top pharmaceutical stock that has seen a 12% return in 2025. The firm’s Q4 2024 earnings report on Feb. 6 showed strong sales of GLP-1 drugs, driving the stock’s rise.

Lilly’s revenue grew by 45% and earnings doubled, beating estimates by 6%. Mounjaro and Zepbound, containing tirzepatide, showed significant growth in treating type 2 diabetes and obesity.

Lilly is gaining market share on Novo Nordisk in the U.S. incretin analogs market, with Zepbound outperforming Wegovy by 47% in weight loss studies.

Lilly has production capacity to prevent sales bottlenecks and expects Phase 3 trial results of orforglipron in 2025, potentially expanding accessibility to incretin drugs with a pill form.

Analysts see nearly 15% upside in Lilly shares, with long-term potential for market growth in the pharmaceutical industry. The company’s success in the incretin market gives it an edge for future growth.



Read more at Nasdaq:: Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial